🔥🐔 BizChicken 🐔🔥
Companies Similar to Alnylam Pharmaceuticals, Inc.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Bio-Path Holdings, Inc.
DNAbilize
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused RNAi nano particle drug development company, developing products based on the DNAbilize technology. The company is advancing its lead drug candidate, prexigebersen, for the treatment of AML and myelodysplastic syndrome.
Symbol: BPTH
Recent Price: $1.17
Industry: Biotechnology
CEO: Mr. Peter H. Nielsen MBA
Sector: Healthcare
Employees: 10
Address: 4710 Bellaire Boulevard, Bellaire, TX 77401
Phone: 832 742 1357
Leadership
- Peter Nielsen, Chief Executive Officer, Chief Financial Officer
- Ana Tari Ashizawa, PhD, MBA, Senior Vice President of Research, Development & Clinical Design
- Anthony Price, MBA, Senior Vice President of Finance, Accounting & Administration
- Michael Hickey, MBA, Vice President of Clinical Operations
- Michael Roberts, Director of Manufacturing Planning & Engineering
- Chairman of the Board,
- President,
- Heath Cleaver, Director
- Paul Aubert, Director
- Douglas P. Morris, Director
- Aline Sherwood, Director
Last updated: 2024-12-31
Alector, Inc.
AL001, AL101, AL002, AL003, AL044
Alector, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for neurodegeneration diseases. The company has several products in various stages of clinical trials aimed at treating conditions such as Alzheimer's, Parkinson's, and frontotemporal dementia.
About | Vision/Values | History | Leadership | Contact | Culture | Vision/Values | History | About | About | About | About | Careers | About | About
Symbol: ALEC
Recent Price: $1.72
Industry: Biotechnology
CEO: Dr. Arnon Rosenthal Ph.D.
Sector: Healthcare
Employees: 245
Address: 131 Oyster Point Boulevard, South San Francisco, CA 94080
Phone: 415 231 5660
Leadership
- Arnon Rosenthal, Ph.D., Co-Founder, Chief Executive Officer, and Director
- Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development
- Marc Grasso, M.D., Chief Financial Officer
- Gary Romano, M.D., Ph.D., Chief Medical Officer
- Danielle Pasqualone, Ph.D., J.D., General Counsel
- Clare Hunt, M.B.A., Chief People Officer
- Kristina Cutter, M.P.H., Chief Regulatory, Pharmacovigilance, and Quality Assurance Officer
- Virginia DeJesus-Rueff, M.B.A., Chief of Staff and Head of Strategy
- Norah Conway, Senior Vice President, Portfolio and Program Management
- Neil Berkley, M.S., M.B.A., Chief Business Officer
- Louis J. Lavigne Jr., M.B.A., Chairperson of the Board
- Elizabeth Garofalo, M.D., Board Member
- Paula Hammond, Ph.D., Board Member
- Richard H. Scheller, Ph.D., Board Member
- David Wehner, Board Member
- Kristine Yaffe, M.D., Board Member
- Errol De Souza, Ph.D., Board Member
- Mark Altmeyer, M.B.A., Board Member
Last updated: 2024-12-31
Alnylam Pharmaceuticals, Inc.
ONPATTRO
Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. It targets genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases.
About | Leadership | DEI | About | About | About | About | About | About | Contact | Careers | Careers | Careers | Careers | Jobs | News | News | Careers | Careers | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Culture | Jobs | About | News | News | News | News | Careers | News | News | Careers | About | About | About | About | About | About | About | Jobs | About
Symbol: ALNY
Recent Price: $236.01
Industry: Biotechnology
CEO: Dr. Yvonne L. Greenstreet M.B.A., MBChB
Sector: Healthcare
Employees: 2100
Address: 675 West Kendall Street, Cambridge, MA 02142
Phone: 617 551 8200
Leadership
- Yvonne Greenstreet, Chief Executive Officer
- Pushkal Garg, Chief Medical Officer
- Jeff Poulton, Chief Financial Officer
- Kelley Boucher, Chief Human Resource Officer
- Timothy Maines, Chief Technical Operations and Quality Officer
- Tolga Tanguler, Chief Commercial Officer
- Piyush Sharma, Chief Ethics & Compliance Officer
- Evan Lippman, Chief Corporate Development & Strategy Officer
- Kevin Fitzgerald, Chief Scientific Officer
- Amy W. Schulman, Chair
- Dennis A. Ausiello,
- Carolyn Bertozzi,
- Michael W. Bonney,
- Olivier Brandicourt,
- Margaret A. Hamburg,
- Peter N. Kellogg,
- David E.I. Pyott,
- Colleen F. Reitan,
- Phillip A. Sharp,
- Elliott Sigal,
Last updated: 2024-12-31
Allarity Therapeutics, Inc.
Stenoparib, Dovitinib, IXEMPRA, Li Pla Cis, 2X-111
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing oncology therapeutics using companion diagnostics and drug response predictor technology.
Careers | Careers | Careers | About | About | About | About | About | About | About | About | Contact | Contact | Contact | Careers | About | About | About | About | About | About | About | About
Symbol: ALLR
Recent Price: $1.12
Industry: Biotechnology
CEO: Mr. Thomas H. Jensen
Sector: Healthcare
Employees: 5
Address: 210 Broadway, Cambridge, MA 02139
Phone: 401 426 4664
Last updated: 2024-12-31
Omeros Corporation
Narsoplimab
Omeros Corporation is a commercial-stage biopharmaceutical company that focuses on discovering, developing, and commercializing therapeutics for inflammation, immune-related cancers, and addictive disorders.
Symbol: OMER
Recent Price: $9.74
Industry: Biotechnology
CEO: Dr. Gregory A. Demopulos M.D.
Sector: Healthcare
Employees: 198
Address: The Omeros Building, Seattle, WA 98119
Phone: 206 676 5000
Last updated: 2024-12-31
Oncternal Therapeutics, Inc.
zilovertamab, ONCT-216, ONCT-808, ONCT-534
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in oncology therapies for cancers with significant unmet medical needs, featuring a pipeline that includes the monoclonal antibody zilovertamab and various other targeted treatments.
Symbol: ONCT
Recent Price: $0.53
Industry: Biotechnology
CEO: Dr. James B. Breitmeyer M.D., Ph.D.
Sector: Healthcare
Employees: 27
Address: 12230 El Camino Real, San Diego, CA 92130
Phone: 858 434 1113
Last updated: 2024-12-31
Sarepta Therapeutics, Inc.
EXONDYS 51, VYONDYS 53, AMONDYS 45, SRP-5051, SRP-9001, SRP-9003
Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on developing RNA-targeted therapeutics and gene therapies for rare diseases, including treatments for Duchenne muscular dystrophy.
Contact | About | Leadership | About | About | About | Locations | About | About | About | About
Symbol: SRPT
Recent Price: $121.19
Industry: Biotechnology
CEO: Mr. Douglas S. Ingram Esq.
Sector: Healthcare
Employees: 1314
Address: 215 First Street, Cambridge, MA 02142
Phone: 617 274 4000
Leadership
- Douglas S. Ingram, President and Chief Executive Officer
- Bilal Arif, Executive Vice President, Chief Technical Operations Officer
- Diane Berry, PhD, Executive Vice President, Chief Global Policy & Advocacy Officer
- Ryan E. Brown, JD, Executive Vice President, Chief General Counsel
- Ian M. Estepan, Executive Vice President, Chief Financial Officer
- Dallan Murray, Executive Vice President, Chief Customer Officer
- Alison Nasisi, Executive Vice President, Chief People Officer
- Louise R. Rodino-Klapac, PhD, Executive Vice President, Head of R&D, Chief Scientific Officer
- Will Tilton, Senior Vice President, Head of Strategy, Chief of Staff
- M. Kathleen Behrens, PhD, Chairwoman
- Richard J. Barry,
- Kathryn Boor, PhD,
- Michael Chambers,
- Deirdre Connelly,
- Stephen L. Mayo, PhD,
- Claude Nicaise, MD,
- Hans Wigzell, MD, PhD,
- John C. Martin, PhD (In Memoriam),
- Annemieke Aartsma-Rus, PhD,
- Carsten Bönnemann, MD,
- Joy Cavagnaro, PhD, DABT, Fellow ATS,
- Kay Davies, PhD, DBE FMedSci FRS,
- Steven Gray, PhD,
- Angela J. Russell, DPhil,
Last updated: 2024-12-31
Acrivon Therapeutics, Inc. Common Stock
Acrivon Predictive Precision Proteomics
Acrivon Therapeutics is a clinical stage biopharmaceutical company developing oncology medicines using a proteomics-based platform to identify patient responders. Their lead candidate, ACR-368, is in Phase 2 trials for various cancers.
Symbol: ACRV
Recent Price: $5.41
Industry: Biotechnology
CEO: Dr. Peter Blume-Jensen M.D., Ph.D.
Sector: Healthcare
Employees: 58
Address: 480 Arsenal Way, Watertown, MA 02472
Phone: 617-207-8979
Last updated: 2024-12-31
Aileron Therapeutics, Inc.
ALRN-6924
Aileron Therapeutics, Inc. is a clinical stage oncology company developing ALRN-6924 for various cancer treatments, with multiple clinical trials in progress.
Symbol: ALRN
Recent Price: $2.32
Industry: Biotechnology
CEO: Dr. James Brian Windsor Ph.D.
Sector: Healthcare
Employees: 15
Address: 285 Summer Street, Boston, MA 02210
Phone: 617 995 0900
Last updated: 2024-12-31
Apollomics, Inc.
APL-101 (Vebreltinib), APL-102, APL-122
Apollomics, Inc. is a biotechnology company that discovers and develops oncology therapies to address unmet medical needs, focusing on treatments for non-small cell lung cancer, liver cancer, breast cancer, esophageal cancer, and brain tumors.
Symbol: APLM
Recent Price: $10.13
Industry: Biotechnology
CEO: Dr. Guo-Liang Yu Ph.D.
Sector: Healthcare
Employees: 45
Address: 989 East Hillsdale Blvd, Foster City, CA 94404
Phone: 650 209 4055
Last updated: 2024-12-31
Ardelyx, Inc.
tenapanor
Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for gastrointestinal and cardiorenal therapeutic areas, including treatments for irritable bowel syndrome with constipation and hyperphosphatemia.
About | Vision/Values | Leadership | About | About | About | About | Contact | About | About | About
Symbol: ARDX
Recent Price: $5.25
Industry: Biotechnology
CEO: Mr. Michael G. Raab
Sector: Healthcare
Employees: 267
Address: 400 Fifth Avenue, Waltham, MA 02451
Phone: 510 745 1700
Leadership
- Justin Renz, Chief Financial & Operations Officer
- Eric Foster, Chief Commercial Officer
- Elizabeth Grammer, Esq., Chief Legal & Administrative Officer
- Laura Williams, MD MPH, Chief Medical Officer
- Robert Blanks, MS RAC, Chief Regulatory Affairs & Quality Assurance Officer
- David Rosenbaum, PhD, Chief Development Officer
- Mike Kelliher, Executive Vice President, Corporate Development and Strategy
- Charon Spencer, Chief Human Resources Officer
- David Mott, Chairman
- Robert Bazemore, Director
- William A. Bertrand, Jr., JD, Director
- Muna Bhanji, R.Ph, Director
- Onaiza Cadoret-Manier, Director
- Mike Raab, Director
- Richard Rodgers, Director
Last updated: 2024-12-31
BioCryst Pharmaceuticals, Inc.
ORLADEYO
Bio Cryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering novel, oral, and small-molecule medicines, with marketed products including RAPIVAB and ORLADEYO, and a pipeline featuring BCX9930, BCX9250, and Galidesivir.
About | About | About | Contact | Careers | Careers | Safety | Jobs | Careers | About | About | About | About
Symbol: BCRX
Recent Price: $7.53
Industry: Biotechnology
CEO: Mr. Jon P. Stonehouse
Sector: Healthcare
Employees: 536
Address: 4505 Emperor Boulevard, Durham, NC 27703
Phone: 919 859 1302
Last updated: 2024-12-31
Context Therapeutics Inc.
onapristone extended release (ONA-XR)
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing cancer treatments for women in the United States. Its main product, ONA-XR, is aimed at resistant female hormone-dependent cancers.
Symbol: CNTX
Recent Price: $1.06
Industry: Biotechnology
CEO: Mr. Martin A. Lehr
Sector: Healthcare
Employees: 5
Address: 2001 Market Street, Philadelphia, PA 19103
Phone: 267 225 7416
Last updated: 2024-12-31
Karyopharm Therapeutics Inc.
XPOVIO
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing drugs targeting nuclear export for the treatment of cancer and other diseases, with a flagship product named XPOVIO.
Symbol: KPTI
Recent Price: $0.70
Industry: Biotechnology
CEO: Mr. Richard A. Paulson M.B.A.
Sector: Healthcare
Employees: 325
Address: 85 Wells Avenue, Newton, MA 02459
Phone: 617 658 0600
Leadership
- Richard Paulson, President and Chief Executive Officer
- James Accumanno, Chief Compliance Officer
- Brian Austad, Senior Vice President, Pharmaceutical Sciences
- Sohanya Cheng, Chief Commercial Officer and Head of Business Development
- Lisa DiPaolo, Chief Human Resources Officer
- Mike Mano, Senior Vice President and General Counsel
- Michael Mason, Chief Financial Officer
- Stuart Poulton, Chief Development Officer
- Reshma Rangwala, Chief Medical Officer & Head of Research
- Amama Sadiq, Senior Vice President, Global Medical and Scientific Affairs
- Elhan Webb, Senior Vice President, Investor Relations
- Garen Bohlin, Director
- Barry E. Greene, Lead Director
- Mansoor Raza Mirza, MD, Director
- Richard Paulson, MBA, President and Chief Executive Officer
- Christy J. Oliger, Director
- Deepa R. Pakianathan, PhD, Director
- Chen Schor, Director
- Zhen Su, MD, MBA, Director
Last updated: 2024-12-31
Outlook Therapeutics, Inc.
ONS-5010
Outlook Therapeutics, Inc. is a late clinical-stage biopharmaceutical company focused on developing and commercializing monoclonal antibodies for ophthalmic indications, with its lead product candidate ONS-5010 in Phase-III clinical trial for treating wet age-related macular degeneration and other retina diseases.
About | About | Leadership | Directors | About | Contact | Careers | Careers | Careers | Jobs | About | About
Symbol: OTLK
Recent Price: $1.86
Industry: Biotechnology
CEO: Mr. C. Russell Trenary III
Sector: Healthcare
Employees: 24
Address: Building F, Iselin, NJ 08852
Phone: 609 619 3990
Leadership
- Randy Thurman, Executive Chairman
- Yezan Haddadin, Member of the Board of Directors
- Kurt J. Hilzinger, Member of the Board of Directors
- Julia A. Haller, MD, Member of the Board of Directors
- C. Russell Trenary III, President, Chief Executive Officer, and Member of the Board
- Lawrence A. Kenyon, Chief Financial Officer and Member of the Board
- Faisal G. Sukhtian, Executive Director
- Julian Gangolli, Member of the Board of Directors
- Gerd Auffarth, MD, Member of the Board of Directors
- Andong Huang, Vice President, Business Development
Last updated: 2024-12-31
Phathom Pharmaceuticals, Inc.
vonoprazan
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases, with significant advancements in the use of vonoprazan in clinical trials.
Symbol: PHAT
Recent Price: $8.00
Industry: Biotechnology
CEO: Ms. Terrie J. Curran
Sector: Healthcare
Employees: 452
Address: 100 Campus Drive, Florham Park, NJ 07932
Phone: 877 742 8466
Last updated: 2024-12-31
Phio Pharmaceuticals Corp.
INTASYL therapeutic platform
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics using its INTASYL therapeutic platform to target tumor and immune cells by regulating genes of the immune system, focusing on products like PH-762, PH-894, and PH-804 for enhancing cancer immunotherapies in adoptive cell transfer.
Symbol: PHIO
Recent Price: $1.90
Industry: Biotechnology
CEO: Mr. Robert J. Bitterman
Sector: Healthcare
Employees: 8
Address: 257 Simarano Drive, Marlborough, MA 01752
Phone: 508 767 3861
Last updated: 2024-12-31
Sonnet BioTherapeutics Holdings, Inc.
SON-1010, SON-080
Sonnet Bio Therapeutics Holdings, Inc. is a clinical stage oncology-focused biotechnology company developing biologic medicines using its human albumin binding technology. The company is based in Princeton, New Jersey, and has lead candidates such as SON-1010 for non-small cell lung cancer, and SON-080 for neuropathies.
Symbol: SONN
Recent Price: $1.48
Industry: Biotechnology
CEO: Dr. Pankaj Mohan Ph.D.
Sector: Healthcare
Employees: 12
Address: 100 Overlook Center, Princeton, NJ 08540
Phone: 609-375-2227
Leadership
- Pankaj Mohan, Ph.D., Founder, CEO & Chairman
- Jay Cross, Chief Financial Officer
- John K. Cini, Ph.D., Chief Scientific Officer & Co-Founder
- Susan Dexter, Chief Technical Officer
- Richard Kenney, M.D., Chief Medical Officer
- Albert Dyrness, Board Member
- Nailesh Bhatt, Chief Executive Officer & Board Member
- Raghu Rao, Board Member
- Donald Griffith, Financial Controller
- Lori McNeill, Board Member
Last updated: 2024-12-31
Enanta Pharmaceuticals, Inc.
N/A
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases, with targets including respiratory syncytial virus, SARS-Co V-2, human metapneumovirus, and hepatitis B virus.
About | Leadership | Directors | Contact | Careers | Careers | Culture | About | About | About
Symbol: ENTA
Recent Price: $5.85
Industry: Biotechnology
CEO: Dr. Jay R. Luly Ph.D.
Sector: Healthcare
Employees: 145
Address: 500 Arsenal Street, Watertown, MA 02472
Phone: 617 607 0800
Leadership
- Jay R. Luly, Ph.D., President, Chief Executive Officer and Director
- Tara L. Kieffer, Ph.D., Chief Product Strategy Officer
- Matthew P. Kowalsky, J.D., Chief Legal Officer
- Brendan Luu, Chief Business Officer
- Paul J. Mellett, Chief Financial and Administrative Officer
- Yat Sun Or, Ph.D., Chief Scientific Officer
- Scott T. Rottinghaus, M.D., Chief Medical Officer
- Bruce L.A. Carter, Ph.D., Chairman of the Board
- Mark G. Foletta, Board Member
- Yujiro S. Hata, Board Member
- Kristine Peterson, Board Member
- Lesley Russell, MBChB, MRCPb, Board Member
- Terry Vance, Board Member
Last updated: 2024-12-31
Ionis Pharmaceuticals, Inc.
RNA-targeted therapeutics
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States, offering treatments like SPINRAZA, TEGSEDI, and WAYLIVRA, while developing medicines in phase 3 studies for various indications including TTR amyloidosis, severe hypertriglyceridemia, and amyotrophic lateral sclerosis.
About | About | About | DEI | DEI | DEI | DEI | Contact | Contact | Careers | Careers | Careers | Careers | Careers | Careers | About | About | News | About | About | ESG | DEI | DEI | About | About | About | Management | About | About | About | About | About | About | About | About | About | About | Careers | Careers | Careers | Careers | Careers | ESG | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | About | About | About | About | About | About | About | Jobs | About | About
Symbol: IONS
Recent Price: $34.92
Industry: Biotechnology
CEO: Dr. Brett P. Monia Ph.D.
Sector: Healthcare
Employees: 927
Address: 2855 Gazelle Court, Carlsbad, CA 92010
Phone: 760 931 9200
Last updated: 2024-12-31